Morrisville, N.C. (PRWEB) February 18, 2009
Clinipace, a growing clinical research solutions company, today announced that it has been selected by two pharmaceutical firms to deploy its TEMPO™ for Grant Management solution.
Life science firms are highly cognizant of the multiple pressures to be transparent and compliant in their funding of investigator initiated research (IIR), and are turning to Clinipace in increasing numbers to help them better manage this process. Funding this research is a strategic investment, and maximizing return is critical whether in the form of publications, useful data or stronger community relationships.
Funding investigator-initiated research, in the form of grants, has become an important part of the overall clinical development program, for drugs and devices. This research furthers scientific understanding of real-world clinical profile and product utilization, identifies new indications, and augments the medical literature. As a result, medical affairs departments in many life science companies have established centralized IIR grant management functions and processes.
"Clinipace offers the only software management system that enables life science firms to centralize the application and evaluation process across the portfolio, while simultaneously empowering investigators with the tools and know-how to support individual research projects, all within one software platform. This ensures visibility and success for all stakeholders," said Jeff Williams, Chief Executive Officer at Clinipace.
Clinipace is an experienced clinical research solutions company providing on-demand software and clinical services for phase I-IV clinical trials, registries, and investigator-initiated grant management programs. We serve biopharmaceutical and medical device companies as well as academic medical centers. Optimized by TEMPO™, our web-based software platform, we deliver services such as EDC, ePRO, grant management, data management, monitoring, site management, and biostatistics at a 30% - 50% savings compared to similar service providers.